site stats

Thor-707 il-2

WebHere we report on the discovery of a site-specific, covalently-pegylated IL-2 that has substantially improved pharmacologic properties over native IL-2 for expansion of Tregs. … WebTHOR-707 is a reprogrammed, site-directed, single pegylated, recombinant human IL-2 (rIL-2) variant that lacks binding affinity for the α chain of the IL-2 receptor. Because THOR …

Interim late-breaking clinical data validate not-alpha …

WebTHOR-707, the IL-2 variant moiety binds to dimers containing the IL-2 receptor beta and gamma chains (IL2Rbg; IL2Rbetagamma) on immune cells activating these cells and inducing their expansion. It also induces the expression of certain cytotoxic cytokines. WebAccueil / Essais cliniques / Etude de phase 2 multicentrique, non randomisée, en ouvert, à plusieurs cohortes évaluant le bénéfice clinique du SAR444245 (THOR-707) associé à d’autres thérapies anticancéreuses pour le traitement de patients atteints de cancer du poumon ou de mésothéliome pleural. synechiae uterine pregnancy what happens https://tomanderson61.com

5 takeaways from AACR, one of the year

WebSince it cannot bind to IL2Ra expressed on innate lymphoid cells in the vascular endothelium, THOR-707 prevents IL-2-mediated recruitment and activation of eosinophils, and inhibits the induction of eosinophil-mediated vascular leak syndrome (VLS). Pegylation also extends the half-life of THOR-707. Compared to recombinant IL-2, THOR-707 allows ... WebPart 2 patients (pts) received escalating doses of THOR-707 with pembrolizumab 200 mg IV (Cohort C) following a 3+3 DED to identify the MTD and/or RP2D of the combination. Conclusions THOR-707 demonstrated encouraging biomarker data analogous to the not-α IL-2 effect observed in preclinical models with no indicators of VLS in this ongoing trial. WebJul 1, 2024 · IL-2 displays a promising potential in the treatment of autoimmune diseases because of its ability to selectively promote T reg cells at low doses. Nevertheless, the clinical application of IL-2 faces a dilemma because of its paradoxical effects on inducing effector cells (i.e., T eff and NK cells) at high doses, as well as its short half-life, making it … synechiae without cells and flare

THOR-707: Using synthetic biology to reprogram the therapeutic …

Category:481 Phase 1/2 study of THOR-707 (SAR444245), a pegylated …

Tags:Thor-707 il-2

Thor-707 il-2

Engineering IL-2 to Give New Life to T Cell Immunotherapy

WebSanofi bet big on engineered IL-2 in 2024, dropping $2.5 billion to acquire Synthorx and its lead program, THOR-707. Now, the French pharma is reporting early phase 1 data … WebBackground THOR-707 (SAR444245) is a recombinant human IL-2 molecule irreversibly bound to a PEG chain to block alpha-binding while retaining near-native affinity for beta/gamma IL-2 receptor subunits. We report updated results from the ongoing HAMMER phase 1/2 trial. Methods SAR444245 was given via IV infusion as monotherapy Q2W [A] or …

Thor-707 il-2

Did you know?

Web2 LIVE PRESENTATIONS Saturday, April 10 1:30 -3:30 p.m. EDT 21-LB-5330-AACR: Clinical Trials Minisymposium Early Clinical Trials with New ... LB041: THOR-707 (SAR444245), a novel not-alpha IL-2 as monotherapy and in combination with pembrolizumab in advanced / metastatic solid tumors: Interim results from HAMMER, ... WebTHOR-707 half-life was about 10 h and there were no reported anti-drug antibodies (against IL-2 or PEG). Overall, these results demonstrate the safety and tolerability of an IL-2 variant that has bias for the IL-2Rβ/γ, leading to successful induction of CD8 T-cells and NK cells while avoiding significant Treg stimulation ( 16 ).

WebBackground THOR-707 (SAR444245) is a recombinant human IL-2 molecule irreversibly bound to a PEG chain to block alpha-binding while retaining near-native affinity for … WebFeb 17, 2024 · In addition, this enhanced binding to CD122 is not seen in competitors IL-2 variants, with both THOR-707 and NKTR-214 showing decreased affinity for CD122 compared to native IL-2.

Webthreesubunits:IL-2Rα (CD25),IL-2Rβ (CD122),andthecommonγ-chain(γ c;CD132).The intermediate-affinity IL-2 receptor is the heterodimer IL-2Rβγ c,which is expressed by naïve andmemoryCD4+ andCD8+ Tcells,andNKcells;thehigh-affinityIL-2receptoristhehet- erotrimerIL-2Rαβγ WebAug 9, 2024 · In mice, administration of THOR-707 results in large-scale activation and amplification of CD8 + T cells and NK cells, without Treg expansion characteristic of IL-2. …

WebTHOR-707, a novel not-alpha IL-2, promotes all key immune system anti-tumoral actions of IL-2 without eliciting vascular leak syndrome (VLS) Author M.E. Milla

WebFeb 14, 2024 · THOR-707, a Novel Not-alpha IL-2, Promotes All Key Immune System Anti-tumoral Actions of IL-2 Without Eliciting Vascular Leak Syndrome (VLS) 2024-09-16 Engineered From an Expanded Genetic Alphabet for the Potential Treatment of Autoimmune Disorders Marcos E. Milla, Carolina E. Caffaro, Lina Ma, Ingrid B. Joseph, David B. Chen, … synechion incWebJul 1, 2024 · Abstract. THOR-707 (SAR444245) is a recombinant human IL-2 molecule that includes a PEG moiety irreversibly bound to a novel amino acid via click chemistry to … synechia treatmentWebJan 27, 2024 · PDF Interleukin-2 (IL-2) is integral to immune system regulation. Its opposing immunostimulatory and immunosuppressive actions make it an attractive ... THOR-707 + CPI PEG-IL-2R ... synechia of uterusWebTHOR-707. Non-alpha, PEGylated version of IL-2: Phase I/ II. NCT04009681 Autotelic Bio: ATB-301. TGF-β2 Targeting Antisense Oligonucleotide (ASO) and IL-2: Phase I. NCT04862767 Roche: RG6279 . PD1-IL2v: Interleukin-2 variant (IL2v), fused with an anti-PD1 protein: Phase I. NCT4303858 EMD Lexigen: thai massage wien 1220WebAnalysts at Jefferies called the data “intriguing” while noting it is currently hard to tell whether the drug improves on the IL-2 pathway agonist Bristol Myers Squibb is developing in ... synechien therapieWebOct 29, 2024 · *THOR-707 (SAR444245) is a non-alpha IL-2 candidate with a best-in-class profile currently being evaluated in Phase 1 trials for the treatment of solid tumors PARIS – October 29, 2024 – Sanofi ... synechie cervicaleWebTHOR-707 was designed to have advantages of current IL-2 therapies. THOR-707 is a variant of recombinant human IL-2 that is pegylated at one site so that it blocks engagement of the high affinity IL-2 receptor alpha chain. This extends the half-life of the drug and increases tumor distribution and retention. thai massage wien 1160